Decheng Capital LLC
- SEC CIK
- 0002010850
- Latest filing
- Aug 14, 2026
Holdings in Q2 2025
Holdings as of Jun 30, 2025, filed Aug 13, 2025. Long positions only; changes compare share counts with Q1 2025.
- Positions
- 25
- −2 vs. Q1 2025
- Portfolio value
- $396.0M
- +$39.5M (+11.1%) vs. Q1 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CGONCG Oncology, Inc. | COM | 6,371,669 | $165.7M | 41.8% | 00.0% | Unchanged | History |
| AARDAardvark Therapeutics, Inc. | COM | 3,917,299 | $53.0M | 13.4% | 00.0% | Unchanged | History |
| NUVBNuvation Bio Inc. | COM CL A | 25,954,439 | $50.6M | 12.8% | 00.0% | Unchanged | History |
| UPBUpstream Bio, Inc. | COM | 3,285,293 | $36.1M | 9.1% | 00.0% | Unchanged | History |
| NAMSNewAmsterdam Pharma Co N.V. | ORDINARY SHARES | 770,000 | $13.9M | 3.5% | 00.0% | Unchanged | History |
| BYSIBeyondSpring Inc. | SHS | 4,531,481 | $10.6M | 2.7% | −351,170−7.2% | Reduced | History |
| MRUSMerus N.V. | COM | 189,098 | $9.95M | 2.5% | 00.0% | Unchanged | History |
| KRYSKrystal Biotech, Inc. | COM | 66,000 | $9.07M | 2.3% | +1,000+1.5% | Added | History |
| MLTXMoonLake Immunotherapeutics | COM CL A | 181,600 | $8.57M | 2.2% | +10,000+5.8% | Added | History |
| RVMDRevolution Medicines, Inc. | COM | 226,000 | $8.31M | 2.1% | 00.0% | Unchanged | History |
| ACRSAclaris Therapeutics, Inc. | COM | 4,041,736 | $5.74M | 1.4% | 00.0% | Unchanged | History |
| LYELLyell Immunopharma, Inc. | COM | 595,466 | $5.26M | 1.3% | 00.0% | UnchangedConverted for a 1-for-20 split | History |
| ACLXArcellx, Inc. | COMMON STOCK | 547,609 | $4.46M | 1.1% | +497,609+995.2% | Added | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 143,000 | $4.11M | 1.0% | −34,958−19.6% | Reduced | History |
| AURAAura Biosciences, Inc. | COM | 515,555 | $3.23M | 0.8% | 00.0% | Unchanged | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 1,323,327 | $1.54M | 0.4% | −696,435−34.5% | Reduced | History |
| EQEquillium, Inc. | COM | 4,447,308 | $1.40M | 0.4% | 00.0% | Unchanged | History |
| FDMT4D Molecular Therapeutics, Inc. | COM | 239,510 | $888.6K | 0.2% | −96,005−28.6% | Reduced | History |
| RCUSArcus Biosciences, Inc. | COM | 160,000 | $811.2K | 0.2% | −648,789−80.2% | Reduced | History |
| ILMNIllumina, Inc. | COM | 7,979 | $761.3K | 0.2% | −3,770−32.1% | Reduced | History |
| LEGNLegend Biotech Corp | SPONSORED ADS | 20,000 | $709.8K | 0.2% | −80,000−80.0% | Reduced | History |
| GRALGRAIL, Inc. | COM | 9,684 | $498.0K | 0.1% | 00.0% | Unchanged | History |
| PYXSPyxis Oncology, Inc. | COMMON STOCK | 326,810 | $359.5K | 0.1% | 00.0% | Unchanged | History |
| RZLTRezolute, Inc. | COM NEW | 59,900 | $267.2K | 0.1% | +59,900 | New | History |
| Nuvation Bio Inc.67080N119 | *W EXP 07/07/202 | 646,057 | $127.3K | <0.1% | 00.0% | Unchanged | – |
Sold out since Q1 2025 (3)
Positions held at the end of Q1 2025 that are gone from this filing.